Conference or Workshop Item
Preparation for HIV vaccine trials in Africa: barriers and facilitators for the establishment of a community advisory board in Burkina Faso. (2009)
Berthe, A; Meda, N; Traore, IT; Some, J; Salouka, S; Sanou, L; Some, F; Rouamba, J; Ouedraogo, D; M'Boutiki, G; Mayaud, P; Nagot, N; van de Perre, P
['material/summary:fileicon_text/html' not defined]
Cost and cost effectiveness of Herpes simplex virus-type 2 (hsv-2) suppressive therapy in HIV-1 and HSV-2 infected women in Johannesburg, South Africa. (2009)
Devine, A; Meyer-Rath, G; Foss, A; Vickerman, P; Edwards, M; Bachmann, M; Mayaud, P; Delany-Moretlwe, S
Dynamic modelling of HSV-2 transmission: issues in structural uncertainty. (2007)
Foss, AM; Vickerman, P; Chalabi, Z; Watts, C; Mayaud, P; Weiss, H; Ramesh, BM; Reza-Paul, S; Washington, R; Blanchard, J; Moses, S; Lowndes, C; Alary, M
Exploring the interactions between HSV-2 and HIV: model predictions for a southern Indian setting. (2008)
Foss, AM; Vickerman, P; Mayaud, P; Weiss, H; Ramesh, BM; Reza-Paul, S; Washington, R; Lowndes, CM; Alary, M; Watts, C
Modeling the interactions between HSV-2 and HIV: implications for the HIV epidemic in southern India. (2007)
Foss, AM; Vickerman, P; Watts, C; Mayaud, P; Weiss, H; Ramesh, BM; Reza-Paul, S; Washington, R; Lowndes, CM; Alary, M
Could HSV-2 suppressive therapy using valacyclovir be a cost-effective strategy for reducing HIV disease progression and transmission among HIV-1 infected women in South Africa? (2012)
Vickerman, P; Devine, A; Foss, A; Delany-Moretlwe, S; Mayaud, P; Meyer-Rath, G
Modelling the cost-effectiveness of HSV-2 suppressive therapy for reducing HIV progression and infectivity among HIV infected women in South Africa. (2009)
Vickerman, P; Devine, A; Meyer-Rath, G; Foss, A; Delany-Moretlwe, S; Mayaud, P